Cargando…
Genetically engineered lymphocytes in metastatic melanoma: TIL 1383I TCR transduced T-cells are detectable after infusion
Autores principales: | Regan, Courtney, Nishimura, Michael, Clark, Ann Lau, Moxley, Kelly, Scurti, Gina, Slepushkin, Vladimir, Roy, Andre, Schonely, Kathy, Dropulic, Boro, Clark, Joseph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991194/ http://dx.doi.org/10.1186/2051-1426-1-S1-P31 |
Ejemplares similares
-
4322 Structure-guided design of the TIL1383I T cell receptor
por: Alonso, Jesus, et al.
Publicado: (2020) -
The transfer of genetically engineered lymphocytes in melanoma patients: a Phase I dose escalation study
por: Regan, Courtney, et al.
Publicado: (2015) -
Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response
por: Wang, Siao-Yi, et al.
Publicado: (2021) -
Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions
Publicado: (1996) -
1383. Characterizing Real-world Patterns of Early Childhood Vaccination
por: Butler, Anne M, et al.
Publicado: (2020)